Back to top
more

Inogen (INGN)

(Delayed Data from NSDQ)

$8.69 USD

8.69
111,109

-0.04 (-0.46%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $8.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Chemed (CHE) Beats on Q3 Earnings, Raises 2018 Guidance

by Zacks Equity Research

The expansion in adjusted operating margin at Chemed (CHE) raises investor hopes on the stock.

Inogen (INGN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cerner's (CERN) Q3 Earnings Match Estimates, Bookings Up Y/Y

by Zacks Equity Research

Cerner (CERN) gains from strong segmental revenues in the third quarter. Guidance for 2018 is impressive.

Zacks.com featured highlights include: ABIOMED, Inogen, Turtle Beach, MCBC and Rush Enterprises

by Zacks Equity Research

Zacks.com featured highlights include: ABIOMED, Inogen, Turtle Beach, MCBC and Rush Enterprises

Merit Medical (MMSI) Tops Q3 Earnings & Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) gains from solid segmental performance in Q3. Also, the company reiterated its guidance for 2018.

Stryker (SYK) Beats Q3 Earnings, Misses Sales Estimates

by Zacks Equity Research

Stryker's (SYK) Q3 results benefit from solid segmental performance. Also, the company sustained strength in International sales.

Varian Medical (VAR) Jumps: Stock Rises 7.7%

by Zacks Equity Research

Varian Medical (VAR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Pick 5 Profitable Stocks With Alluring Net Income Ratio

by Zacks Equity Research

Investors always focus on companies that have a high level of profitability irrespective of the current market scenario.

McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates

by Zacks Equity Research

McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.

Varian (VAR) Misses Earnings, Beats Revenue Estimates in Q4

by Zacks Equity Research

Varian's (VAR) Q4 results benefit from strong growth in Oncology Systems. Also, solid guidance boosts investors' optimism.

Is Inogen (INGN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (INGN) Outperforming Other Medical Stocks This Year?

Medidata (MDSO) Tops Earnings & Revenue Estimates in Q3

by Zacks Equity Research

Strong performance in the Subscription revenues segment drives Medidata???s (MDSO) results in Q3. Professional services also posted steady growth.

Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues

by Zacks Equity Research

Strong performance in the Instruments & Accessories and Systems segments drive Intuitive Surgical's (ISRG) top line in Q3.

Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed

by Zacks Equity Research

Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.

Zacks.com featured highlights include: Callaway Golf, Herbalife, IAC/InterActiveCorp, Inogen and Salesforce.com

by Zacks Equity Research

Zacks.com featured highlights include: Callaway Golf, Herbalife, IAC/InterActiveCorp, Inogen and Salesforce.com

Sanghamitra Saha headshot

Bet On 5 Stock Likely to Beat Earnings Estimates

by Sanghamitra Saha

These top-ranked stocks are likely to beat on bottom line in their next releases.

Baxter & ASPEN Launch PN Tools to Boost Clinical Nutrition

by Zacks Equity Research

Baxter (BAX) and ASPEN's SmartPN lends the company a competitive edge in the MedTech space.

Medidata Cloud Manages Echocardiogram Images in WASE Study

by Zacks Equity Research

Medidata's (MDSO) Rave Imaging platform is a cloud-based clinical data management system used to electronically capture, manage and report clinical research data.

Here's Why You Should Hold CONMED Stock in Your Portfolio

by Zacks Equity Research

Despite aggressive rivalry in the MedTech space, CONMED (CNMD) to gain from its unique offerings and an extensive product portfolio.

Here's Why You Should Buy HealthEquity (HQY) Stock Right Now

by Zacks Equity Research

Strong presence in the HSA space and a solid guidance for fiscal 2019 make HealthEquity (HQY) a promising investment pick.

Can Inogen (INGN) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Inogen (INGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Walgreens (WBA) Q4 Earnings Gain From Overall Strength?

by Zacks Equity Research

Several planned developments, early benefits of new pharmacy contracts as well as an increase in volume are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.

    Is Inogen (INGN) Stock Outpacing Its Medical Peers This Year?

    by Zacks Equity Research

    Is (INGN) Outperforming Other Medical Stocks This Year?

      Stryker's HyperBranch Buyout to Boost Neurotechnology Business

      by Zacks Equity Research

      Stryker's (SYK) craniomaxillofacial division's market prospects bright.

        Here's Why You Should Buy Inogen (INGN) Stock Right Now

        by Zacks Equity Research

        Inogen (INGN) is expected to gain from strong international foothold and a raised view for 2018.